Ashley Gallagher, Editor

Important evidence about the health effects of e-cigarettes can help shape public health best practices in the United States, the findings of an analysis suggest.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

The health care company’s analysis evaluates non-specialty and specialty drugs, biosimilars, medication affordability, and the cost of administering COVID-19 vaccines.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

The annual conference includes presentations with educational opportunities related to community pharmacies, health system pharmacies, pharmacy law, public health, and more.

Study results show that individuals hospitalized for acute heart failure are 36% more likely to experience clinical benefit over 90 days if initiated on the drug following stabilization.

The findings highlight the potential of acetaminophen, non-steroidal anti-inflammatory drugs, and opioid analgesics to treat infectious diseases.

Kaléo’s product has received fast-track designation for US military personnel facing this threat on the battlefield.

Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.

Investigators at Penn State find that these medications inhibit certain viral enzymes called proteases that are essential for SARS-CoV-2 replication in infected human cells.

At week 4, there was about a 61.6% decrease for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol and/or are intolerant to other lipid-lowering drugs.

During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.

The agency has given the greenlight to the abbreviated new drug application for the overdose-reversal medication.

The agency addresses the inclusion of older individuals in cancer-studies, the designing and conducting of multiple expansion cohorts, and the expedited development of biologics and drugs.

The median survival time for individuals with SCC and treated with Merck’s pembrolizumab was 13.9 months compared with 8.8 months in the control arm.

Links of chain mail are arranged in the bacteria to form a pattern that prevents molecules from entering the cell.

The drug has achieved both primary endpoints of clinical remission and endoscopic response at week 12 compared with the placebo, the company says.

The results of 2 analyses in the United Kingdom show a small increase in the potential for intracranial thrombosis after vaccination.

Results of studies show that women with obesity who get these weight loss procedures often also have preventative benefits.

The median duration of discomfort and pain was shorter in the vaccinated group than in the placebo group, at 21 days and 24 days, respectively, investigators say.

Patients from more socially vulnerable areas were sicker when they arrived at hospitals but did as well as others by the time of discharge, results of a new analysis show.

Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says.

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

Results of the analysis may help inform future COVID-19 vaccine development, investigators say.

The approval is based on the results of the ACTIVATE and ACTIVATE-T phase 3 studies, Agios Pharmaceuticals says.

Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.

At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.

The treatment for hypertrophic cardiomyopathy met its primary endpoint at week 6 in the phase 3 VALOR-HCM trial, the pharmaceutical company says.

The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.

In the report published by The Lancet, the group provides a brief history of drug use and addiction, describes the opioid landscape, and includes 7 recommendations.